Regulatory October 20, 2021Bulletin from Extraordinary General Meeting in Oasmia Pharmaceutical AB
Non Regulatory September 24, 2021Oasmia to present at Naventus Life Science Summit on September 29
Regulatory September 20, 2021Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB
Oasmia Pharmaceutical published its interim report for the second quarter of 2021 on August 19, 2021, at 08.00 am CEST.
The company will hold a conference call and an online presentation on the same day at 10.00 am CEST. The call will be hosted by CEO Francois Martelet and CFO Fredrik Järrsten. The presentation will be in English.
Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program